Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders
Sovargen has dosed the first patient in a Phase 1b/2a trial of paxalisib for intractable epilepsy linked to focal cortical dysplasia type 2 and tuberous sclerosis complex, triggering a $2 million development milestone payment to Kazia. Under the March 2024 exclusive licensing deal, Sovargen develops and commercializes paxalisib for mTORopathy-related epilepsies worldwide excluding mainland China, Hong Kong, Macao and Taiwan; Kazia remains eligible for up to $17 million in further milestones plus sub-licensing revenue share and royalties on net sales.
Key figures
- Drug Name
- paxalisib
- Phase Of Trial
- Phase 1b/2a
- Milestone payment usd
- 2000000
- Additional milestones potential usd
- 17000000
AI analysis
Red flags3 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.